Molecular Partners, a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, completed a private placement with institutional investors of 5,528,089 shares newly issued out of its authorized share capital by way of an accelerated bookbuilding. The shares were placed at CHF 14.50 per share, resulting in gross proceeds of approximately CHF 80.2 m.The proceeds from the capital increase will be used to fund research & development activities as well as for general corporate purposes.
SVB Leerink LLC, Cowen and Company, LLC, Van Lanschot Kempen Wealth Management N.V. and Credit Suisse AG acted as Joint Bookrunners.
Homburger advised Molecular Partners in this transaction. The team was led by partner Dieter Gericke (Corporate/ M&A – pictured right) and included partner Dieter Grünblatt (Tax) and associates Karin Mattle and Lorenzo Togni (both Corporate/M&A).